The Distinct Pattern of Granulomatous Lobular Mastitis with Erythema Nodosum: More Severe Conditions and Extensive Lesions.

PURPOSE: Granulomatous lobular mastitis (GLM) is a benign inflammatory disease of the mammary gland with unknown etiology. Erythema nodosum (EN) is a rare, extramammary symptom of GLM. The purpose of this article was to investigate the clinical features of EN associated with GLM. METHODS: We recruited 102 GLM patients diagnosed between December 2018 and December 2021 at Renmin Hospital of Wuhan University. The clinical characteristics and laboratory indices of the EN group (n = 12) and the non-EN group (n = 90) were compared. RESULTS: The proportion of GLM patients with lesions involving ≥2 quadrants and high peripheral white blood cell count, absolute neutrophil count and neutrophil-to-lymphocyte ratio (NLR) was larger in the EN group than in the non-EN group (p = 0.002, 0.025, 0.014, 0.002, respectively). The duration of EN was longer in GLM patients with EN than in GLM patients without EN (p = 0.005). GLM patients with EN had more abscesses and sinus tracts than those without EN (p = 0.003, 0.038). Lesions involving ≥2 quadrants and the NLR were positively associated with the occurrence of EN (R = 0.304, 0.0302, p = 0.002, 0.002). Receiver operating characteristic curve analysis revealed that the area under the curve of the NLR was 0.770. When NLR > 5.73, the sensitivity and specificity of predicting EN were 66.67% and 87.78%, respectively. CONCLUSION: Our findings suggest that GLM concomitant with EN suggests the presence of a more severe condition and extensive lesions.

Erythema Nodosum Induced by the Pfizer- BioNTech Vaccine.

A 42-year-old man presented with a painful nodular dermatitis with 38.5°C fever and joint pain, which started overnight. The patient had taken the first dose of Pfizer-BioNTech (Comirnaty, INN-COVID-19 mRNA) vaccine 8 days ago. He denied any kind of recent infections, inflammatory conditions, malignancies, or drugs administration.

Erythema nodosum in children: a cohort study from a tertiary pediatric hospital in Italy.

Erythema nodosum (EN), although relatively uncommon in the pediatric population, is the most frequent type of panniculitis in children. The present study aimed to report all the cases of children admitted to our tertiary pediatric hospital with the diagnosis of EN to evaluate the epidemiology, clinical manifestations, etiology, treatment, and the course of this disease in the pediatric age. This observational study retrospectively considered all children evaluated to the emergency room (ER) of Meyer Children's University Hospital, Florence, Italy, discharged with a diagnosis of EN over a 12-year period (from January 2009 to December 2021). Clinical and laboratory data were recorded using a standardized report form. Sixty-eight patients with EN were included. The etiologic diagnosis of EN was made in 38 children (55.9%): 29 (42.6%) had infection-related EN (in particular EBV and ß-hemolytic streptococcus), 6 (8.8%) had Crohn's disease, 1 celiac disease, 1 Sjogren syndrome, and 1 Hodgkin lymphoma. In 30 patients (45%), no definitive diagnosis was reached, and they were defined as having idiopathic EN. Most of the laboratory tests were nonspecific. No statistical differences were found in the demographic and clinical data, and the main diagnostic laboratory parameters between patients with idiopathic EN versus those with secondary EN.  Conclusion: Since EN can be isolated or the first manifestation of heterogeneous underlying pathologies, some of which can be severe and life-threatening, it is important to recognize it and carry out all the necessary etiological diagnostic investigations to understand its etiology and start the specific treatment. What is Known: • Erythema nodosum (EN) is the most frequent type of panniculitis in children. • It has been associated with a wide spectrum of disorders, such as different types of infection, malignancies, chronic inflammations, and drugs. What is New: • No statistical differences can be found in clinical features as well as laboratory data, between patients with idiopathic EN versus those with secondary EN. • A broad spectrum of investigations and a proper follow-up should be taken into account in order to prevent a delayed or missed secondary EN diagnosis.

Erythema nodosum associated with COVID19 infection: A pediatric case report and review of the literature.

Erythema nodosum (EN) is a common panniculitis characterized by tender erythematous nodules predominantly on the pretibial area and represents a hypersensitivity reaction to multiple triggers. COVID19 infection and vaccination have been associated with EN in the adult population. We report a pediatric case of EN following COVID19 infection and review the literature on COVID19 infection and COVID19 immunization-related EN.

Erythema nodosum after COVID-19 vaccine: Report of two pediatric cases.

With the introduction of large-scale COVID-19 vaccination programs, a variety of cutaneous manifestations have been described. We present two girls (ages 12 and 5 years) who developed erythema nodosum (EN) 3 and 14 days after Pfizer-BioNTech COVID-19 vaccination, respectively. While EN after COVID-19 vaccination has been reported in adults, it is can also occur in children.

Manifestaciones cutáneas asociadas a enfermedad inflamatoria intestinal pediátrica. Serie de casos / Cutaneous manifestations associated with paediatric inflammatory bowel disease. Case series

Introducción. Las manifestaciones extraintestinales en la enfermedad inflamatoria intestinal tienen una prevalencia variable de 6 a 47%, dentro de las cuales las manifestaciones cutáneas en la edad pediátrica suponen un 10-15%, siendo las más frecuentes el pioderma gangrenoso y el eritema nodoso. Suelen presentar una adecuada evolución clínica, a pesar de ello es importante realizar un correcto diagnóstico con tratamiento precoz. Presentamos tres casos clínicos de enfermedad inflamatoria intestinal con manifestaciones dermatológicas asociadas. Caso 1. Vasculitis leucocitoclástica asociada a colitis ulcerosa en paciente varón de 11 años. Presenta buena respuesta al tratamiento con corticoterapia e inmunosupresores. Caso 2. Varón de 8 años con eritema nodoso asociado a enfermedad de Crohn. Buena respuesta clínica con nutrición enteral exclusiva e inmunosupresores. Caso 3. Mujer 15 años con psoriasis en gotas asociada a tratamiento con anti-TNF en enfermedad de Crohn. Resolución tras retirada de agente desencadenante. Conclusiones. Las manifestaciones dermatológicas en la edad pediátrica son menos frecuentes que en adultos. De manera habitual tienen un curso leve y autolimitado como es el caso de nuestros dos primeros pacientes. El tercer caso lo presentamos como causa de manifestación cutánea secundaria a tratamiento de mantenimiento de la enfermedad de base (AU)

Introduction. Extraintestinal manifestations in inflammatory bowel disease have a variable prevalence of 6-47%, within which cutaneous manifestations in pediatric age account for 10-15%, the most frequent being pyoderma gangrenosum and erythema nodosum. They usually present an adequate clinical evolution, in spite of this it is important to make a correct diagnosis with early treatment. Our objective is to present three clinical cases of dermatologic manifestations of inflammatory bowel disease from our practice. Case 1. Leukocytoclastic vasculitis associated with ulcerative colitis in an 11-year-old male patient. He presented good response to treatment with corticotherapy and immunomodulator. Case 2. 8-year-old male with erythema nodosum associated with Crohn´s disease. Good clinical response with exclusive enteral nutrition and immunomodulator. Case 3. 15-year-old woman with guttate psoriasis associated with anti-TNF treatment for Crohn´s disease. Resolution after withdrawal of the triggering agent. Conclusions. Dermatological manifestations in pediatric age are less frequent than in adults. They usually have a mild and self-limited course as in the case of our first two patients. The third case is presented as a cause of cutaneous manifestation secondary to maintenance treatment of the underlying disease (AU)

Erythema nodosum as key manifestation of histoplasmosis case.

Histoplasmosis is a systemic infection caused by the fungus, Histoplasma capsulatum Infection of H. capsulatum frequently occurs by inhaling the spores of the fungus, which is found in bat and bird droppings, or soil enriched with their excrement. If not detected and treated, histoplasmosis can develop late, severe complications such as mediastinal fibrosis, or even develop into a disseminated infection. However, histoplasmosis infections are often asymptomatic, making its detection more difficult. Further, only 6% of histoplasmosis cases will present with erythema nodosum, with most cases associated with female patients. This case presents a woman in her 50s with a pertinent history of fibromyalgia and hypothyroidism secondary to Hashimoto's who initially sought medical care for painful nodules on her legs and was eventually diagnosed with histoplasmosis. This report clearly demonstrates the importance of maintaining a broad differential when working up inflammatory manifestations, such as erythema nodosum.

Predictive Factors of Severe Behçet's disease: A Longitudinal, Prospective Cohort Followed Between 1981-2020.

INTRODUCTION: Behçet's disease (BD) is a systemic vasculitis of unknown cause. The spectrum of the disease ranges from mucocutaneous manifestations to other organ diseases with relevant morbidity. Associations between disease severity and male sex, earlier age at onset, and the presence of erythema nodosum have been described. OBJECTIVES: To evaluate clinical factors associated with manifestations of severe disease in a single-center cohort. METHODS: A longitudinal, prospective, unicentric cohort study with patients followed in a specialized outpatient clinic between 1981 and 2020. Severe BD was defined as a Krause total clinical severity score >4 points. RESULTS: We included 243 patients, of whom 31% were male, with an average follow-up time of 14.6 years. Regarding organ manifestations, all patients had mucous manifestations (N=243, 100%), 133 (55%) skin, 104 (43%) joint, 71 (29%) ocular, 48 (20%) vascular, 47 (19%) neurological, 22 (9%) gastrointestinal and 1 (0.4%) cardiac involvement by BD. One hundred fifty-six (64%) patients were classified as having severe BD. Severe BD was more frequent in men (OR=2.004, p=0.024), increasing with age (OR=1.021 per year, p=0.037), in the presence of skin manifestations (OR=4.711, p<0.001), specifically erythema nodosum (OR=8.381, p<0.001), and pseudofolliculitis (OR=2.910, p<0.001). In the multivariate model, variables independently associated with severe BD were male gender (Adjusted OR=1.961, p=0.047), erythema nodosum (Adjusted OR=8.561, p<0.001) and pseudofolliculitis (Adjusted OR=2.372, p=0.007). DISCUSSION: Male gender, erythema nodosum, and pseudofolliculitis were independently associated with severe BD forms and therefore should serve as warning signs to the clinician.

Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma.

A 66-year-old woman receiving pembrolizumab for metastatic melanoma presented with tender red nodules on her shins and forearms. Biopsy was consistent with erythema nodosum (EN). The eruption responded to oral minocycline and potent topical steroids. Subsequent investigations detected bihilar lymphadenopathy, biopsied as granulomatous lymphadenitis, confirming the diagnosis of pembrolizumab-associated sarcoidosis. Pembrolizumab was stopped for two cycles and was restarted without recrudescence of EN or bihilar lymphadenopathy. Immunotherapy-associated sarcoidosis is a rare but recognized adverse event related to therapy with immune checkpoint inhibitors. EN is an uncommon manifestation of immunotherapy-induced sarcoidosis. New-onset bihilar lymphadenopathy in the context of immunotherapy requires prompt histological evaluation to differentiate between immunotherapy-associated sarcoidosis and metastatic progression. We review the literature related to immunotherapy-associated EN.

Pembrolizumab (trade name Keytruda^®) is a type of immune therapy that stimulates the body's immune system to fight cancer cells. This immune therapy can cause a variety of rashes. In this article, we describe a patient who developed a red lumpy rash on her limbs that is not commonly described with pembrolizumab. A woman was diagnosed with advanced melanoma and was treated with pembrolizumab. She developed a red lumpy rash on her arms and legs, and a biopsy showed signs of a condition called erythema nodosum. Treatment with an antibiotic tablet and strong steroid ointment were helpful. Scans of her chest showed signs of sarcoidosis in her lungs, which can be associated with erythema nodosum. Pembrolizumab was stopped, and both the rash and lung sarcoidosis stayed away when it was restarted. This type of rash has rarely been described with this kind of immune therapy, and it can be a sign of lung involvement.

A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.

BACKGROUND AND AIMS: Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. METHODS: As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. RESULTS: For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. CONCLUSIONS: Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.

Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis.

INTRODUCTION: In recent years, the prevalence of inflammatory bowel diseases has been increasing in Japan due to the westernization of lifestyles. Many patients have been reported to have extra-intestinal manifestations (EIMs) at least once. Skin lesions occur with a high degree of frequency among EIMs, with erythema nodosum (EN) and pyoderma gangrenosum (PG) the main complications. Cytapheresis is again attracting attention as a treatment with few side effects. METHODS: We investigated the therapeutic effect of cytapheresis on ulcerative colitis (UC) and cutaneous EIMs. Between 2008 and 2021, 240 patients with active UC had induction therapy by cytapheresis at our hospital. RESULTS: Remission and response rates were 50.0% and 67.5%, respectively. Apheresis was performed on seven patients with PG and five patients with EN with a good response. Serious adverse events were not observed. CONCLUSION: This retrospective assessment of efficacy showed that EN and PG responded favorably to cytapheresis.

[Erythema nodosum due to cat-scratch-disease: An association and important therapeutic implications]. / Érythème noueux compliquant une maladie des griffes du chat : une association et des implications thérapeutiques à connaître.

INTRODUCTION: Cat-scratch disease is a zoonosis caused by Bartonella henselae and transmitted mostly through a break in the skin. This infectious disease is commonly characterized by a benign lymphadenitis. However, more unusual presentations have been observed. CASE REPORT: We report the case of a 44-year-old woman with cat-scratch disease who developed subsequently an erythema nodosum. The non-steroidal anti-inflammatory treatment of the erythema nodosum may have led to worsening of cat-scratch disease with an abscess requiring surgical treatment. CONCLUSION: Cat-scratch disease is an uncommon and poorly known cause of erythema nodosum, and must be systematically ruled out. As non-steroidal anti-inflammatory drug are usually prescribed as a treatment of erythema nodosum, it should be used cautiously to reduce the risk of complications in the cat-scratch disease.